A study by Charlotte’s Web in response to questions from the US Food and Drug Administration (FDA) regarding liver safety among daily CBD users has found no liver toxicity or drowsiness.
The cannabis giant shared the combined conclusions from two cohorts of an industry-sponsored liver safety study, with the second cohort adding another 222 adults who consumed hemp CBD tinctures orally every day for 60 days.
The two groups, totalling 1,061 participants, used 17 commercially available brands and 39 hemp CBD products, with Charlotte’s Web claiming a statistical certainty of 98%.
The investigation’s preliminary findings mirror the first cohort’s results, showing no liver toxicity or clinical liver disease, no product-related adverse events and new data concluding no daytime drowsiness or testosterone deficiency.
Charlotte’s Web co-founder and chief operating officer Jared Stanley said: “We are excited that these two cohorts will provide the FDA with the scientific data the government agency had requested of the CBD industry on liver safety for those who ingest CBD daily.
“These results provide further evidence to support policymakers in shaping a much-needed federal regulatory framework for hemp CBD products.”